Medical Guides & Advanced Cancer Insights

600+ in-depth articles on Japanese heavy-ion therapy, immunotherapy, and precision medicine — stay current on international care and regenerative medicine.

2026-08-19

醫療專欄blog細胞療法

Introduction to Dendritic Cells

Dendritic cells (DCs), named from their initial two English letters, are a critical component of immunotherapy and function as the primary 'police' of the human immune system....

[Lung Cancer Advanced Treatment] Conquering Leptomeningeal Metastases: Osimertinib Demonstrates Strong Intracranial C...

2026-08-19

醫療專欄medical-blog肺癌

[Lung Cancer Advanced Treatment] Conquering Leptomeningeal Metastases: Osimertinib Demonstrates Strong Intracranial C...

A literature summary of the BLOOM trial's design and primary endpoints for Osimertinib in EGFR-mutant non-small-cell lung cancer with leptomeningeal metastases. This article is not treatment advice; any medication decision must be evaluated by your treating oncologist.

2026-08-19

醫療專欄blog

新生抗原是什麼？

之前我們寫了一篇關於日本免疫治療的趨勢後，有幾位跟我們聯繫，是否能夠更加詳盡的介紹樹突細胞。從免疫檢查哨抑制劑（Nivolumab等）的開發以及機制中能夠發現，CTL這種特殊的T淋巴球是相當重要的。因此藉由樹突細胞疫苗讓CTL增加，是對於癌症治療的方法之一。另外，單單的樹突細胞疫苗必須要認識癌細胞才能給予CTL指令，我

FDA Approves Celcuity Breast Cancer Drug — What Patients Should Know

2026-07-18

癌症cancer乳癌

FDA Approves Celcuity Breast Cancer Drug — What Patients Should Know

The FDA has approved a new breast cancer drug by Celcuity, but rollout concerns remain. Here is what international patients considering Japan should understand before acting.

Baricitinib Oral Suspension Now Available in Japan: What Patients Should Know

2026-07-10

癌症cancer

Baricitinib Oral Suspension Now Available in Japan: What Patients Should Know

Eli Lilly Japan has launched a new liquid suspension form of baricitinib (Ormient). Here's what it means for patients considering treatment in Japan.

First FDA-Approved On-Body Injectable Anticancer Drug: What It Means for Patients

2026-07-07

癌症cancer

First FDA-Approved On-Body Injectable Anticancer Drug: What It Means for Patients

The FDA has granted its first approval for a wearable on-body injectable anticancer device. Here's what cancer patients considering treatment abroad should know.

Pembrolizumab in 2025: Combination Reviews, Biosimilar Changes & What It Means for Patients

2026-07-03

癌症cancer免疫療法

Pembrolizumab in 2025: Combination Reviews, Biosimilar Changes & What It Means for Patients

A plain-language summary of recent pembrolizumab-related developments—FDA review of a new combination, next-gen competitors, and biosimilar program changes—and what international patients should consider next.

Celcuity's Breast Cancer Drug Wins FDA Approval: What It Means for Patients Considering Japan

2026-07-02

癌症cancer乳癌

Celcuity's Breast Cancer Drug Wins FDA Approval: What It Means for Patients Considering Japan

The FDA has approved Celcuity's first breast cancer drug. Here's what this US regulatory milestone may — and may not — mean for patients exploring treatment options in Japan.

Fujitsu Launches Digital Medical Certificate Service Adopted by Japan Cancer Institute Hospital

2026-07-02

癌症cancer

Fujitsu Launches Digital Medical Certificate Service Adopted by Japan Cancer Institute Hospital

A new digital system connecting hospital documentation and insurance in Japan — what it means for patients considering cancer care at major Japanese centers.

Enhertu Gets EU Approval as First Tumour-Agnostic HER2-Directed ADC

2026-06-30

癌症cancerADC藥物

Enhertu Gets EU Approval as First Tumour-Agnostic HER2-Directed ADC

The EU has approved Enhertu for previously treated HER2-positive metastatic solid tumours — the first tumour-agnostic HER2-directed antibody drug conjugate approval. Here's what it means for patients considering treatment options.

Ropeginterferon Alfa-2b Receives FDA Approval for Polycythemia Vera

2026-06-24

癌症cancer

Ropeginterferon Alfa-2b Receives FDA Approval for Polycythemia Vera

The FDA has approved ropeginterferon alfa-2b-njft (BESREMi Pen™) for polycythemia vera in the U.S. Here's what patients considering overseas treatment should know.

Lupin Receives US FDA Tentative Approval for a Prostate Cancer Drug

2026-06-23

癌症cancer前列腺癌

Lupin Receives US FDA Tentative Approval for a Prostate Cancer Drug

Lupin has received a US FDA tentative approval for a prostate cancer drug — what this regulatory step means, and what patients considering treatment in Japan should know.

Aprepitant Injectable Emulsion Receives FDA Approval for Supportive Oncology Care

2026-06-16

癌症cancer

Aprepitant Injectable Emulsion Receives FDA Approval for Supportive Oncology Care

The FDA has approved Aprepitant Injectable Emulsion by Azurity Pharmaceuticals. Here is what cancer patients considering treatment in Japan should know.

Gene Therapy for Bladder Cancer: A Bladder-Preserving Option Now Approved in Japan

2026-06-15

癌症cancer膀胱癌

Gene Therapy for Bladder Cancer: A Bladder-Preserving Option Now Approved in Japan

Ferring Pharma's Adstiladrin intravesical solution, a gene therapy for BCG-unresponsive bladder cancer, has received regulatory approval in Japan — here's what it means for patients considering treatment abroad.

First-Line Liver Cancer Drug from Elevar Therapeutics Awaits July 2026 FDA Decision

2026-06-15

癌症cancer肝癌

First-Line Liver Cancer Drug from Elevar Therapeutics Awaits July 2026 FDA Decision

Elevar Therapeutics CEO expects an FDA decision on a first-line liver cancer drug around July 23, 2026, with no outstanding review issues — what this may mean for patients exploring treatment options.

FDA Oncology Roundup: New Approvals in Drugs, Imaging Agents, and Diagnostics

2026-06-13

癌症cancer

FDA Oncology Roundup: New Approvals in Drugs, Imaging Agents, and Diagnostics

The FDA has approved new oncology drugs, imaging agents, and diagnostics. Here is what it means for patients considering treatment in Japan.

Momelotinib Granted Orphan Drug Status in US & EU for VEXAS Syndrome

2026-06-13

癌症cancer

Momelotinib Granted Orphan Drug Status in US & EU for VEXAS Syndrome

GSK's momelotinib has received Orphan Drug Designations in both the US and EU for VEXAS syndrome — a regulatory milestone, not yet a treatment approval. Here's what it means for patients.

FDA Approves Guardant Health Test to Identify Patients for Boehringer's New Cancer Drug

2026-06-06

癌症cancer

FDA Approves Guardant Health Test to Identify Patients for Boehringer's New Cancer Drug

The FDA has approved a Guardant Health companion diagnostic to help identify eligible patients for a new Boehringer Ingelheim cancer drug. Here's what it means for patients exploring treatment options.

Lenalidomide Capsules Receive Additional Approval in Japan: What Patients Should Know

2026-06-06

癌症cancer

Lenalidomide Capsules Receive Additional Approval in Japan: What Patients Should Know

Sawai Pharmaceutical announced expanded indications and dosage approval for Lenalidomide Capsules in Japan — here is what it may mean for patients considering treatment there.

Gan-Ken Ariake Hospital and J&J Launch Oncology Clinical Research Collaboration in Japan

2026-06-04

癌症cancer

Gan-Ken Ariake Hospital and J&J Launch Oncology Clinical Research Collaboration in Japan

One of Japan's top cancer hospitals has partnered with J&J to advance clinical trials — here's what it may mean for patients considering treatment in Japan.

Replimune's Skin Cancer Drug Gets a Third Shot at US Approval

2026-06-04

癌症cancer

Replimune's Skin Cancer Drug Gets a Third Shot at US Approval

Replimune has been given a third opportunity to seek US approval for a skin cancer drug. Here's what this regulatory development means for patients considering treatment in Japan.

Ga-68 PSMA-11 Generic Radiodiagnostic Receives FDA Approval for Prostate Cancer

2026-06-03

癌症cancer前列腺癌

Ga-68 PSMA-11 Generic Radiodiagnostic Receives FDA Approval for Prostate Cancer

RadioMedix has received U.S. FDA approval for a generic Ga-68 PSMA-11 imaging agent for prostate cancer. Here's what it means for patients considering care abroad.

Welireg + Keytruda Approved as Adjuvant Therapy for Kidney Cancer After Surgery

2026-06-02

癌症cancer腎癌

Welireg + Keytruda Approved as Adjuvant Therapy for Kidney Cancer After Surgery

Merck's Welireg and Keytruda combination has received regulatory approval for kidney cancer patients following surgery. Here's what it means if you're exploring treatment options.

FDA Approves New AbbVie Drug for Rare Blood Cancer — Key Facts for Patients

2026-05-31

癌症cancer

FDA Approves New AbbVie Drug for Rare Blood Cancer — Key Facts for Patients

The FDA has approved a new AbbVie drug for a rare blood cancer. Here's what international patients considering treatment in Japan should know before taking next steps.

Japan Advisory Panel Recommends Etocama (カミゼストラント) and Other Cancer Medicines

2026-05-31

癌症cancer

Japan Advisory Panel Recommends Etocama (カミゼストラント) and Other Cancer Medicines

Japan's pharmaceutical advisory committee has recommended approval for AstraZeneca's anticancer medicine Etocama and 10 other items — what this means for patients considering treatment in Japan.

FDA Approves New ADC for a Rare Blood Cancer — What Patients Should Know

2026-05-28

癌症cancerADC藥物

FDA Approves New ADC for a Rare Blood Cancer — What Patients Should Know

The FDA has approved an ADC therapy developed by ImmunoGen (AbbVie) for a rare blood cancer. Here's what this means for patients considering treatment abroad, including in Japan.

FDA Grants Full Approval to Imatinib (Gleevec) for Adjuvant GIST Treatment

2026-05-25

癌症cancer標靶治療

FDA Grants Full Approval to Imatinib (Gleevec) for Adjuvant GIST Treatment

The FDA has issued full approval for imatinib (Gleevec) in adjuvant GIST treatment. Here is what this U.S. decision may mean for patients considering care in Japan.

AbbVie ADC Drug Wins FDA Approval for an Ultra-Rare Blood Cancer

2026-05-24

癌症cancerADC藥物

AbbVie ADC Drug Wins FDA Approval for an Ultra-Rare Blood Cancer

The FDA has approved an AbbVie antibody-drug conjugate (ADC) for an ultra-rare blood cancer. Here's what this means for patients considering treatment options in Japan.

DECNUPAZ Gets FDA Approval for Blood Cancer: What Patients Should Know

2026-05-24

癌症cancer

DECNUPAZ Gets FDA Approval for Blood Cancer: What Patients Should Know

AbbVie's DECNUPAZ has received FDA approval for blood cancer. Here's what this means for patients considering treatment options in Japan.

Replimune's Cancer Drug Gets a Third FDA Approval Attempt After Renewed Talks

2026-05-23

癌症cancer標靶治療

Replimune's Cancer Drug Gets a Third FDA Approval Attempt After Renewed Talks

Replimune has resubmitted a cancer therapy for FDA approval after two prior rejections. Here's what patients considering treatment in Japan should know right now.